1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Gabather AB (publ)

Gabather AB (publ)

GABA.ST
Gabather AB (publ)SE flagStockholm Stock Exchange
0.03
SEK
+0.00
- -
8.13MMarket Cap
Gabather AB (publ)
GABA.ST
(Stockholm Stock Exchange)

Recent

price

0.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.51
-0.55
-0.69
-1.01
-0.57
-0.29
-0.33
-0.16
-0.17
-0.37
-0.02
-0.02
Basic EPS, GAAP
- -
-0.68
-0.5
-0.68
-1
-0.56
-0.27
-0.31
-0.18
-0.21
-0.16
-0.04
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.55
-0.98
-1.35
-2.64
-2.54
-1.52
-1.84
-1.98
-2.02
-5.78
-0.59
-0.38
Book Value per Share
- -
0.83
1.88
1.76
0.75
1.71
0.52
0.21
0.06
0.01
-0.2
- -
0.01
Tangible Book Value per Share
- -
12
14
20
20
25
52
52
53
56
21
192
294
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-6
-8
-14
-20
-14
-15
-17
-9
-9
-8
-5
-5
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
8
10
27
35
15
43
28
11
3
-4
-4
-1
3
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
9
13
33
36
16
44
28
11
3
- -
-4
1
3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
236
431
610
Market Capitalization
5
5
14

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1
4
7
Cash, Cash Equivalents & STI
1
3
6
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
5
4
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-103.89%
-258.03%
-115.86%
Free Cash Flow
13.99%
8.36%
117.07%
Net Income, GAAP
4.59%
-16.69%
-40%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.05
-0.02
-0.02
-0.02
-0.37
2025
-0.01
-0.01
-0.01
-0.01
-0.02
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Extrawell Pharmaceutical Holdings Limited (0858.HK)
GelStat Corporation (GSAC)
Nexien BioPharma, Inc. (NXEN)
Bio Essence Corporation (BIOE)
ScinoPharm Taiwan, Ltd. (1789.TW)
Medicamen Biotech Limited (MEDICAMEQ.BO)
Business
Gabather AB (publ) is a pharmaceutical company concentrating on the development of novel drug candidates designed to address various central nervous system disorders. The firm’s research primarily targets significant unmet medical needs across conditions such as neuropsychiatric disorders, including psychoses, depression, anxiety, chronic pain, and cognitive impairments like Alzheimer's disease. Its lead compound, GT-002, a GABAA receptor modulator, has successfully advanced through initial clinical trials and is currently progressing into Phase II studies for conditions such as schizophrenia. Established in 2014, the company operates from Södertälje, Sweden.